Vaccines and Public Health
Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.
Payer Experiences with COVID-19
New Avalere research featuring payer views of COVID-19 finds a heightened concern about the clinical effectiveness of related future vaccines and therapeutics, a substantial reduction in preventive services due to the COVID-19 public health emergency, and a significant uptick in telehealth adoption.
Interview: Designing Pull Funding for a COVID-19 Vaccine
Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study in which a simulation was used to determine whether pull funding could overcome issues related to speed, scaling, and pricing for a COVID-19 vaccine.
COVID-19 and Influenza Vaccine Distribution Stakeholder Considerations
The convergence of the seasonal influenza and the current COVID-19 vaccines will merge several distribution considerations for a diverse group of stakeholders.
How Do Biden’s and Trump’s Public Health Platforms Compare?
The November 2020 election is widely anticipated to have important implications for how the US responds to COVID-19.
The COVID-19 Impact on US Routine and Seasonal Vaccine Administrations
Avalere conducted a national survey of more than 200 independent primary care providers concerning the impacts of the COVID-19 pandemic on their ability to support continued vaccination programs for patients. Over 90% of respondents indicated the COVID-19 pandemic has increased operating costs and led to revenue loss. Eighty-two percent indicated that an increase in vaccine administration fees would aid sites in overcoming barriers arising from the COVID-19 pandemic, and 75% expressed interest in implementing new care delivery arrangements to facilitate immunizations during the COVID-19 pandemic.
Using Diagnostics to Mitigate the COVID-19 Public Health Emergency
Mitigating the public health emergency (PHE) caused by SARS-CoV-2 requires a multifaceted approach.
Interview: Community Use of Face Masks and COVID-19: Evidence from a Natural Experiment of State Mandates in the US
Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study on the effectiveness of statewide mask mandates in reducing the spread of COVID-19, and the implications of its findings on future policy interventions.
Who Will Approve a COVID Vaccine in the US?
As life sciences companies sprint toward COVID-19 vaccines and therapies, the discussion below considers who has the authority to make the call on their availability at the Food and Drug Administration (FDA) and the US Department of Health and Human Services (HHS).
Interview: Vaccines Outlook: Hesitancy, Uptake, and Infrastructure with Dr. Angela Shen
Tune into another episode of Start Your Day with Avalere. In this segment, vaccines experts Richard Hughes IV and Dr. Angela Shen discuss the issue of vaccine hesitancy and the gaps in infrastructure and policy that affect adult vaccine uptake.
CMS Proposal Would Increase Provider Payment for Vaccine Administration
The proposed CY 2020 MPFS rule includes provisions that, if finalized, would increase provider reimbursement for vaccine administration. However, the proposed crosswalk of the codes to a separate, nonvaccine related code could subject the code to future unrelated payment fluctuations.
Interview: Vaccines Outlook: Adult Vaccine Access with Abby Bownas
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss challenges within the vaccines marketplace and highlight the efforts currently underway to improve access and uptake among adults.
Bringing COVID-19 Vaccines and Therapeutics to Market
On July 22, Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics in the “Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics” webinar. They examined FDA regulatory considerations, coverage and access challenges, and key pricing and distribution scenarios for optimal US market access.
Interview: 2020 Mid-Year Vaccines Outlook
Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss the general outlook for the vaccines marketplace and pipeline.
Avalere Vaccines: 2020 Mid-Year Outlook
Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.
Webinar: Cutting Through the Noise: Market Evolution and Pathways to Access for COVID-19 Vaccines and Therapeutics
Avalere experts discussed the marketplace for COVID-19 vaccines and therapeutics, including key decision points for regulatory pathways, pricing, and distribution scenarios for optimal US and EX-US market access.
The State of COVID-19 Vaccine Candidate Development
The novel coronavirus (COVID-19) was first reported in Wuhan, China, on December 31, 2019, and within a month was declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO).
Medicare Spent $106B on Vaccine-Preventable Diseases Over 3 Years
Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.
Post-COVID-19 Considerations for the Commercial Health Coverage Market
Faced with a rapidly evolving healthcare environment, there are a number of important uncertainties that commercial insurers will need to consider when planning for the future
Opportunities to Modernize the Vaccine Injury Compensation Program
A proposal to eliminate shoulder injuries from the list of vaccine-related conditions that warrant federal compensation through the National Vaccine Injury Compensation Program (VICP) highlights the administrative challenges posed by these claims and provides an opportunity to consider reforms to modernize the program.
COVID-19 is Stressing a Fractured Mental Healthcare System in the US
Mental Health Awareness Month and the COVID-19 crisis intersect—and highlight challenges in the US mental health care system